The Life Sciences team advised Eidos Therapeutics, Inc., BridgeBio International GmbH and BridgeBio Europe B.V. in their exclusive license agreement with Bayer Consumer Care AG to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in Europe. In consideration for the license grant, Eidos is entitled to receive up to $310 million in upfront, regulatory, and sales milestone payments through 2026, and is eligible for additional payments subject to the achievement of certain sales milestones. In addition, Eidos is entitled to receive royalties according to a tiered structure starting in the low thirties percent.

Eidos, headquartered in Palo Alto, CA and an affiliate of BridgeBio Pharma, Inc. (Nasdaq: BBIO), is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing acoramidis, a potentially disease-modifying therapy for the treatment of ATTR.

The Goodwin team consisted of Noelle Dubiansky, Richard Hoffman, Emily Beman, and Katerina Stavrianidis (IPTS); Jessica Rothstein (IP); Gretchen Scott and Curtis McCluskey (Data Privacy); Alexander Varond (Regulatory & Compliance); Dan Karelitz (Tax); Paul Jin, Eram Khan, Anuj Ghai, Charlotte Jane Brunsdon and Sophie Entwisle (Antitrust); Kathleen Ryan (Private Equity); Maggie Wong and Alicia Tschirhart (Corporate); with invaluable assistance from Frank Ruofan Qin and Jo-an Chen.

For additional details on the agreement, please read the press release.